# 1 Comparison and analysis of various complementary diagnosis methods

## 2 for the current situation and problems of COVID-19 diagnosis

3

4 Hee Jin Huh<sup>1</sup>, Seok Lae Chae<sup>1</sup>, Dong-Min Kim<sup>2,\*</sup>

<sup>1</sup>Department of Laboratory Medicine Dongguk University Ilsan hospital.

<sup>2</sup>Department of Internal Medicine, College of Medicine, Chosun University, 588 Seosuk-dong, Dong-gu, Gwangju
 61453, Republic of Korea.

- 8 \*Correspondence and requests for materials should be addressed to Dong-Min Kim (Tel: 82-62-220-3108; Fax: 82-
- 9 62-234-965; E-mail address: drongkim@chosun.ac.kr)
- 10 Article received/accepted date, online published date
- **11** © Society and Springer 2010
- 12

### 13 Abstract

- 14 We evaluated and compared the diagnostic performance of fluorescence immunoassay (FIA) and two types of
- serological diagnostic tests: enzyme-linked immunosorbent assay (ELISA) and immunochromatographic assay
- 16 (ICA) for detection of SARS-CoV-2 antigen and antibody to diagnose COVID-19 infections. This study is aimed to
- analyze and compare the current status and problems of COVID-19 diagnosis and various alternative diagnostic
- 18 methods that are viable. The enrolled subjects in our study population were tested with real-time polymerase chain
- 19 reaction (RT-PCR). ELISA and immunochromatographic diagnostic kit were used to diagnose 362 positive and
- 20 3010 negative SARS-CoV-2 specimens, and antigen fluorescence immunoassay kit was used on 62 positive and 70
- 21 negative SARS-CoV-2 RT-PCR confirmed samples for diagnosis. As a result, categorizing by the patient symptom
- onset days, PCL COVID19 Total Ab EIA (ELISA) showed the sensitivity of 93.4% from 15 to 21 days, 94.2% from
- over 22 days, and the specificity of 99.97%. PCL COVID19 IgG/IgM Rapid Gold (ICA) had a sensitivity of 86.9%,
- 24 97.4%, and the specificity of 98.14% respectively. PCL COVID19 Ag Rapid FIA sensitivity was 93.8% from 0 to 7
- days, 71.4% from 8 to 12 days and specificity was 98.57%. In conclusion, COVID-19 Ab ELISA and ICA, and
- 26 COVID-19 Ag FIA are all complementary and applicable diagnostic methods to resolve the current problems of
- 27 COVID-19 diagnosis.
- 28

#### 29 KEYWORDS

- 30 COVID-19, ELISA, Fluorescent Immunoassay, immunochromatography, real-time polymerase chain
- 31 reaction
- 32
- 33 Introduction:

With the first identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
in December 2019 from Wuhan, Hubei Province, China, coronavirus disease 2019 (COVID-19)
was soon after declared as a pandemic in March 2020 by World Health Organization (WHO)<sup>1</sup>.
The virus has not ceased to spread until now, resulting in tremendous public health challenges
across the world with over 61 million confirmed cases reported worldwide as of 30 November
2020<sup>2, 3</sup>.

7 COVID-19 diagnostic test samples are obtained from either a patient's blood or naso-

8 oropharyngeal specimen. Molecular diagnostic tests, such as next generation sequencing or real-

9 time polymerase chain reaction (RT-PCR), have been recommended to detect SARS-CoV-2

10 from the upper and lower respiratory tract swab samples for COVID-19 diagnosis<sup>3-7</sup>. However,

11 this method requires at least for 6 or more hours, to accurately process and determine the

12 COVID-19 infection of a patient<sup>8</sup>. In many cases where steep COVID-19 surges occur,

13 performing the molecular tests in a timely manner to close the gap between the high number of

14 patients and the limited number of laboratories has been a critical hinderance from devising of

15 efficient containment strategies for COVID-19 in many countries<sup>9</sup>.

16 In order to solve this problem, serological tests such as enzyme-linked immunosorbent assay

17 (ELISA) and immunochromatography have been developed to detect antibodies and antigens of

18 a virus. These methods now have become commercialized and can be easily accessed. This

19 allows to play a crucial role in overcoming the limitation of molecular diagnostic test as

20 alternative assays with the advantages such as ability to test large numbers of samples more

21 rapidly with less cost and perform an epidemiologic tracing in a short period of time<sup>10, 11</sup>.

22 Proper isolation and timely detection through a rapid diagnosis of COVID-19 is critical to

23 prevent the spreading of infection among the patients with recurrence of COVID-19, and to

24 decrease the associated prevalence and mortality rates due to unforeseen waves of the pandemic<sup>8</sup>,

<sup>12</sup>. Therefore, we evaluated and compared the diagnostic performance of two types of serological

26 diagnostic test ELISA and ICA for antibody detection and FIA for antigen detection of SARS-

27 CoV-2.

28

29

30 Methods:

#### **1** Study Design for serological test

2 A total of 50 patients diagnosed as COVID-19 positive were enrolled in this study. All enrolled 3 patients were confirmed to be infected with SARS-CoV-2 by the RT-PCR assays using 4 nasopharyngeal swabs. In the case of negative samples, 1072 residual samples were collected 5 from 1072 healthy people assessed by physical examination during early November of 2019, 6 before the pandemic of COVID-19, and the others collected from healthy donors without any 7 COVID-19 symptoms. A total of 3,372 human blood samples (serum), 362 COVID-19 positive 8 samples and 3,010 negative samples were used for this study. Regarding anticoagulant, 3372 9 serum samples were separated with gel without any anticoagulants. Positive and negative blood 10 samples for COVID-19 were used for the performance evaluation of the PCL COVID-19 Total 11 Ab EIA and the PCL COVID19 IgG/IgM Rapid Gold at DUMC under respective IRB approval 12 (DUIH 2020-03-025-003 and 110757-202003-HR-02-02). The performance evaluation was 13 conducted retrospectively by comparing the information including test results of the RT-PCR 14 COVID-19.

#### 15 Study Design for Antigen test

16 In case of antigen test, we used nasopharyngeal swab samples in viral transport medium (VTM) 17 and the extraction buffer (the PCL COVID19 Ag Rapid FIA kit). A total of 132 nasopharyngeal 18 swab samples stored in VTM, including 62 positives and 70 negatives for the COVID-19, were used for the retrospective performance evaluation of the PCL COVID19 Ag Rapid FIA at 2 19 20 institutions under respective IRB approval (S-IRB-2020-004-04-08 and IRB-2020-01-027). 21 Nasopharyngeal swab samples were collected from individuals diagnosed as positive or negative 22 by RT-PCR testing (PowerChekTM2019-nCoV Real-time PCR Kit, Kogenebiotech, Seoul, 23 Korea).

24

#### 25 **RT-PCR confirmation assay**

Nasopharyngeal swabs were obtained from each patient for RT-PCR, which was performed
using the CFX96<sup>TM</sup> Real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA) with

1	the All	plex <sup>™</sup> 2019-nCoV	Assav kit (	Seegene Inc.	Seoul, Korea	) according to the
<b>-</b>			Tibbuy Kit	beegene me.,	beoul, norea	, according to the

- 2 manufacturer's instructions. The assay is designed to detect RdRP and N genes specific for
- 3 SARS-CoV-2, and E gene for all of *Sarbecovirus* including SARS-CoV-2.
- 4

5	Serologic test for detection of antibodies against SARS-CoV-2
6	Lateral flow immunochromatographic assay (LFA)
7	To evaluate SARS-CoV-2 specific IgM and IgG antibodies, the LFA based rapid test (PCL
8	COVID19 IgG/IgM Rapid Gold) was performed following the manufacturer's instructions. Each
9	sample was tested by one test and readout (positive/negative) interpreted by two operators in
10	parallel.
11	
12	Enzyme-linked immunosorbent assay (ELISA)
13	To evaluate total antibody response, the ELISA (PCL COVID19 Total Ab EIA test, PCL Inc.,
14	Seoul, Korea) was performed following the manufacturer's instructions. All tests were performed
15	in duplicate, according to the manufacturer's instructions and Absorbance/cut-off values $\geq 1.0$
16	were considered positive.
17	
18	Fluorescence Immunochromatographic Assay (FIA)
19	To detect the SARS-CoV-2 virus infection, the rapid FIA kit (PCL COVID19 Ag Rapid FIA),
20	which is used with the PCLOK EZ analyzer for the qualitative detection from SARS-CoV-2 in
21	nasopharyngeal specimens from individuals who are suspected of COVID-19 by their healthcare
22	provider, was performed following the manufacturer's instrument.
23	

24 Statistical analysis

- 1 The sensitivity, specificity, positive predictive value (PPV), and negative predictive value
- 2 (NPV) were calculated, along with the 95% confidence interval (CI). A diagnostic value test of
- 3 the ELISA and rapid antibody method was performed with MedCalc software, version 19.5.1
- 4 (Mariakerke, Belgium).
- 5

#### 6 **Results**

#### 7 Population of study sample

8 The overall contents of the study population are described (Table 1). For the Ab test, 362 blood 9 samples were collected from 50 patients identified as COVID-19 positive via RT-PCR test and 10 3010 negative blood samples were collected from 3010 individuals. For the Ag test, 62 positive 11 and 70 negative samples identified as COVID-19 were collected through RT-PCR testing. Each 12 population was categorized by patient specimen collection dates, the presence of COVID-19 13 symptoms, pre-existing disease, and age. 14

15 Result of SARS-CoV2 Ab test

In order to compare the positive rate of PCL COVID19 Total Ab EIA and PCL COVID19 16 17 IgG/IgM Rapid Gold to RT-PCR, the obtained results were first categorized into 4 groups by the 18 length of days after symptom onset: 0-7 days, 8-14 days, 15-21 days, and 22+ days. The positive 19 rate of PCL COVID19 Total Ab EIA diagnostic results for 362 samples, confirmed positive with 20 RT-PCR, was 40% (95% CI 24.86-56.67%), 65.7% (95% CI 53.40-76.65%), 93.4% (95% CI 21 84.05-98.18%) and 94.2% (95% CI 89.93-97.09%) respectively. For IgG & IgM combined 22 positive rates of PCL COVID19 IgG/IgM Rapid Gold diagnostics for 362 identical samples was 23 42.5% (95% CI 27.04-59.11%), 64.3% (95% CI 51.93-75.39%), 86.9% (95% CI 75.78-94.16%), 24 and 97.4% (95% CI 94.00-99.14%) respectively. We also measured the positive rate marked 25 with IgG and IgM individually; IgG showed a result of 32.5% (95% CI 18.57-49.13%), 50.0% 26 (95% CI 37.80-62.20%), 83.6% (95% CI 71.91-91.85%) and 97.4% (95% CI 94.00-99.14%), 27 and IgM showed 37.5% (95% CI 22.73-54.20%), 51.4% (95% CI 39.17-63.56%), 77.0% (95% 28 CI 64.5-86.85%), and 65.4% (95% CI 58.24-72.16%) accordingly. This data demonstrated that

IgG and IgM showed a similar positive rate until the 14 days period, but we noticed that the 1 2 positive rate of IgG began to gradually increase from 14 days and onwards (Figure 1). 3 For PCL COVID19 Total Ab EIA, specificity was measured with a total of 3010 individual 4 serum samples. Only 1 out of 3010 negative samples was a false negative, resulting in specificity of 99.97% (95% CI 99.82-100%) (Table 2). For PCL COVID19 IgG/IgM Rapid Gold, out of 5 6 3010 negative samples, 2954 samples were diagnosed as negative and the rest of 56 samples 7 came out as false positives, showed a specificity of 98.14% (95% CI 97.59-98.59%) (Table2). 8 Within the 50 COVID-19 positive patient groups, seroconversion has occurred to 16 of them 9 and we decided to analyze the effect of seroconverted samples on positive rate results of PCL 10 COVID19 Total Ab EIA diagnostic kit. This data was also categorized by the length of days 11 after symptom onset of the patient: 0-7 days, 8-14 days, 15-21 days, and 22+ days, and the result 12 showed as 17.4% (95% CI 4.95-38.78%), 51.2% (95% CI 35.13-67.12%), 90.5% (95% CI 69.62-98.83%), and 92.1% (95% CI 84.99-96.52%) respectively (Figure 2). For antibody detection 13 14 diagnostics, we observed that the positive rate dramatically increases after 14 days from the 15 infection of the virus. In addition, by comparing the results from patients with the presence or absence of disease 16 17 (Figure 4B), it was confirmed that the antibody concentration was high in patients with 18 underlying disease. 19 Taken together, it seems that SARS-CoV-2 antibody should be tested after 14 days of infection, 20 and SARS-CoV-2 antigen should be tested within 14 days of infection. 21

#### 22 Result of SARS-CoV2 Ag test

23 We used PCL COVID19 Ag Rapid FIA to distinguish the patients who have been infected for 24 less than 14 days. With having all 62 samples already confirmed positive with RT-PCR test (0-25 12 days after symptom onset), the test result demonstrated that sensitivity was 93.8% (95% CI 26 82.80-98.69%) for 0-7 days period and 71.4% (95% CI 41.90-91.61%) for 8-12 days period 27 (Figure 3). We can conclude that the positive rate for antigen-based tests decreases as days go by 28 from the initial symptom onset period of a patient. Specificity was measured with a total of 70 29 RT-PCR confirmed negative samples, and only 1 out of 70 samples was false negative, resulting 30 in specificity of 98.57% (95% CI 92.30-99.96%) (Table 2).

#### 1

#### 2 **Discussion**

3 In Wuhan, Hubei Province, China, coronavirus disease 2019 (COVID-19) was declared a 4 pandemic in March 2020 by the World Health Organization (WHO) with the first detection of 5 extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 20191. The 6 WHO announced that Chinese authorities had identified a novel type of coronavirus in January 7 7 2020<sup>13</sup>. RT-PCR, a nucleic acid amplification test (NAAT), was used as a COVID-19 diagnostic 8 test in many countries around the world, since the new coronavirus was identified 4-7. However, 9 the RT-PCR test takes a lot of time to accurately diagnose the infection. To combat the current 10 COVID-19 pandemic, an efficient strategy for diagnosis of asymptomatic infections is required 11 because it is difficult to discern solely with a symptom-based RT-PCR screening. Asymptomatic 12 cases are reported to be 20 to 40% of the total incidence, or even higher, considering the percentage of undetected COVID-19 infections<sup>14, 15</sup>. Although there have been no cases 13 previously with the Middle East Respiratory Syndrome coronavirus (MERS-CoV), current 14 15 investigations have shown that asymptomatic and mild COVID-19 patients can produce 16 detectable levels of antibodies against SARS-CoV-19. To manage these problems, the need for 17 an alternative analysis that enables a large number of diagnoses in a short time at low cost has emerged. In fact, RT-PCR test does not satisfy the field where antibody results are required 18 19 because antibody test results cannot be obtained through RT-PCR test. In this study, 20 complementary diagnostic products to RT-PCR will be reviewed for COVID-19 detection. These 21 products are COVID-19 total Ab ELISA: PCL COVID19 Total Ab EIA, COVID-19 spike 22 protein, nucleocapsid protein antibody immunochromatographic rapid test: PCL COVID19 23 IgG/IgM Rapid Gold, and COVID-19 nucleocapsid protein antigen fluorescent immunoassay 24 rapid test: PCL COVID19 Ag Rapid FIA. All of the above reagents are a dedicated detection 25 reagent for the SARS-Cov 2. Coronavirus is a single-stranded RNA virus that uses spike protein to enter host cells. 26 27 Coronavirus is composed of spike protein, membrane protein, envelope protein, and

nucleocapsid protein<sup>4, 13</sup>. In general, the diagnosis of COVID-19 infection is made using RT-

29 PCR. While RT-PCR remains an effective microbial diagnostics technique, however, when used

30 alone in the areas of confirming COVID-19, there are some limitations or weaknesses, such as

1 the inability to differentiate virus viability and the development of indeterminate or false-

2 negative results due to low target cell numbers in specimens<sup>16</sup>. To manage these problems,

3 different methods of diagnosis were required for suspected and supervised COVID-19

4 infections.

From the aforementioned reasons, complementary diagnosis is required in addition to the RT-5 6 PCR-based diagnostic method. Among them, COVID-19 Ab Enzyme-Linked Immunosorbent 7 Assay (ELISA), COVID-19 Ab Immunochromatographic rapid test, and COVID-19 Antigen Fluorescent Immunoassay rapid test can be used. ELISA has proven its validity as a diagnostic 8 9 method for a long time since it was published by Peter Perlmann and Eva Engvall in 1971. The 10 fact that ELSIA can be implemented to a large-scale automatized equipment makes it a suitable complementary diagnosis method regarding the current issue with the COVI-19 pandemic. 11 12 Immunochromatography was developed with the aim of detecting antigens in blood in the late 1960s and has been validated as a diagnostic method for various infections. The advantages 13 14 of immunochromatography are its simple test methods, significantly shorter time required to 15 prepare samples and reagents compared to other methods, and inexpensive equipment required 16 for making a diagnosis. Also, it can be applied in various environments both indoor and outdoor settings. Immunochromatography is a suitable complementary diagnosis method for RT-PCR 17 18 test which has limitations such as operation time, operable environment, and number of samples 19 the test can diagnose at once. Lastly, the COVID-19 Nucleocapsid protein Antigen Fluorescent 20 Immunoassay has gone through major developmental breakthroughs over the years, and has 21 shown prominence in reagent simplification, simple analysis design, and high-sensitivity 22 detection. Fluorescent Immunoassay uses a fluorescent compound that absorbs light or energy of a specific wavelength and emits light or energy at another wavelength. This fluorescent 23 24 compound offers an advantage of being able to check the results in a short time using a small 25 analyzer as a detection reagent. PCL COVID19 Total Ab EIA (ELISA) showed the sensitivity of 93.4% from 15 to 21 days, 26

PCL COVID19 Total Ab EIA (ELISA) showed the sensitivity of 93.4% from 15 to 21 days,
94.2% from over 22 day, and the specificity of 99.97%. PCL COVID19 IgG/IgM Rapid Gold
(ICA) had a sensitivity of 86.9%, 97.4%, and the specificity of 98.14% respectively. PCL
COVID19 Ag Rapid FIA sensitivity was 93.8% from 0 to 7 days, 71.4% from 8 to 12 day and
specificity was 98.57%. As a result, these diagnostic methods can be used as a complement to

the current diagnosis of COVID-19, before 14days of infection, SARS-CoV-2 antigen should be
 tested and after 14days of infection, SARS-CoV-2 antibody should be tested.

Acknowledgements This study was supported by the Promising IP Project Support Program
(grant number: 20001089) funded by the Ministry of Trade Industry and Energy. And this study
was supported by the Clinical Trial Support Program (grant number: HI18C1849) funded by the
Ministry of Health and Warfare. Also, this study was supported by the Technological Innovation
R&D Program (grant number: HI20C0371010120) funded by the Korea Health Industry
Development Institute (KHIDI).

- 9
- 10 References:
- 11


World Health Organization. Timeline of WHO's response to COVID-19. Available
 from: <u>https://www.who.int/news/item/29-06-2020-covidtimeline</u>. (2020)

- World Health Organization. A Coordinated Global Research Roadmap. Available from:
   <u>https://www.who.int/publications/m/item/a-coordinated-global-research-roadmap</u>. (2020)
- 16 3. World Health Organization. Coronavirus Disease (COVID-19) Outbreak Situation.
- Available from: <u>https://www.who.int/emergencies/diseases/novel-coronavirus-2019</u>.
  (2020)
- Lu, R., et al., Genomic characterisation and epidemiology of 2019 novel coronavirus:
   implications for virus origins and receptor binding. *Lancet*, **395**, 565-574 (2020)
- Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in
   Wuhan, China. *Lancet*, **395**, 497-506 (2020)
- Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel
  coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*, **395**, 507-513
  (2020)
- 26 7. Guan, W.J., et al., Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl*27 *J Med*, 382, 1708-1720 (2020)
- Choe, J.Y., et al., Diagnostic performance of immunochromatography assay for rapid
   detection of IgM and IgG in coronavirus disease 2019. *J Med Virol*, (2020)

1	9.	World Health Organization. Laboratory testing strategy recommendations for COVID-
2		19: interim guidance, 21 March 2020. Available from:
3		https://apps.who.int/iris/handle/10665/331509. (2020)
4	10.	Ko, J.H., et al., Neutralizing Antibody Production in Asymptomatic and Mild COVID-19
5		Patients, in Comparison with Pneumonic COVID-19 Patients. J Clin Med, 9 (2020)
6	11.	Porte, L., et al., Evaluation of a novel antigen-based rapid detection test for the diagnosis
7		of SARS-CoV-2 in respiratory samples. Int J Infect Dis, 99, 328-333 (2020)
8	12.	Nguyen, T., D. Duong Bang, and A. Wolff, 2019 Novel Coronavirus Disease (COVID-
9		19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics. Micromachines
10		(Basel), <b>11</b> (2020)
11	13.	World Health Organization. Novel Coronavirus (2019-nCoV) situation report-1.
12		Available from: https://www.who.int/docs/default-source/coronaviruse/situation-
13		reports/20200121-sitrep-1-2019-ncov.pdf. (2020)
14	14.	Huff, H.V. and A. Singh, Asymptomatic transmission during the COVID-19 pandemic
15		and implications for public health strategies. Clin Infect Dis, (2020)
16	15.	Oran, D.P. and E.J. Topol, Prevalence of Asymptomatic SARS-CoV-2 Infection : A
17		Narrative Review. Ann Intern Med, 173, 362-367 (2020)
18	16.	Kralik, P. and M. Ricchi, A Basic Guide to Real Time PCR in Microbial Diagnostics:
19		Definitions, Parameters, and Everything. Front Microbiol, 8, 108 (2017)
20		

#### **1** Table 1. Clinical characteristics of study population

		SARS-CoV-2 Ab test		SARS-CoV-2 Ag test	
		Positive	Negative	Positive	Negative
Total		362	3010	62	70
Age range (avg.)		1-88 (59.8)	-	-	-
Disease	Y	207	-	-	-
	Ν	155	-	-	-
Days post symptom	0-7	40	-	-	-
	8-14	70	-	-	-
	15-21	61	-	-	-
	22+	191	-	-	-



1 2 22 +

186 Figure 1. Graph and table of positive rates of total antibody, IgG and IgM and days after

125

186

94.2%

97.4%

65.4%

97.4%


3 symptom onset. Positive rates for the total antibody(measured by PCL COVID19 Total Ab

4 EIA), IgG/IgM(measured by PCL COVID19 IgG / IgM Rapid Gold), were determined in 362

serum samples from 50 patients according to the days after symptom onset. 5

180

191






2 Figure 2. Levels of antibodies against SARS-CoV-2 in patient samples at different times

after symptom onset. SARS-CoV-2 antibody levels were measured for various periods in 16
patients with seroconversion, and the positive rate of antibodies measured within each week was
plotted on the graph. The X shape is less than S/CO 1, the point is S/CO 1 or more. The red
dotted line is S/CO 1(equal to cutoff)

## 1 Table 2. Results of negative test for each kit

	PCL COVID19 Total Ab EIA	PCL COVID19 IgG/IgM Rapid gold	PCL COVID19 Ag Rapid FIA
Total sample	3010	3010	70
Positive	1	56	1
Negative	3009	2954	69
Specificity	99.97%	98.14%	98.57%




[	Day	Total sample No*.	Pos sample No.	Pos rate %	
	0~7	48	45	93.8%	
[	8~12	14	10	71.4%	

1

2 Figure 3. Graphs of positive rates and days after symptom onset of PCL COVID19 Ag

3 Rapid FIA. The positive rate is the result of PCL COVID19 Ag Rapid FIA diagnosis, according

4 to the number of days after onset in 62 RT-PCR positive diagnostic samples.



1 2

2 Figure 4. Antibody levels against SARS-CoV-2 according to the clinical characteristics of

3 the study population. Levels of antibodies against SARS-CoV-2 between patients with or

4 without underlying illness at different times after symptom onset. The X shape is less than S/CO

5 1, the point is S/CO 1 or more. The red dotted line is S/CO 1(equal to cutoff). 16 patients with

6 seroconversion(PCL COVID19 Total Ab EIA result) were picked up and studied.